

Publications/Journals

Ammori BJ, Barclay GR, Larvin M and McMahon MJ.

Hypocalcemia in patients with acute pancreatitis: a putative role for systemic endotoxin exposure. *Pancreas*, 2003; 26: 213-217.

Ammori BJ, Becker KL, Kite P, Snider RH, Nylen ES, White JC, Barclay GR, Larvin M and McMahon MJ.

Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. *Pancreas*, 2003; 27: 239-243.

Atkinson AP, Cedzynski M, Szemraj J, St Swierzko A, Bak-Romaniszyn L, Banasik M, Zeman K, Matsushita M, Turner ML and Kilpatrick DC.

L-ficolin in children with recurrent respiratory infections. *Clin. Exp. Immunol*, 2004; 138: 517-520.

Bessos H, Perez S, Armstrong-Fisher S, Urbaniak S and Turner ML.

The development of a quantitative ELISA for antibodies against human platelet antigen type 1a. *Transfusion*, 2003; 43: 350-356.

Cedzynski M, Szemraj J, Swierzko AS, Bak-Romaniszyn L, Banasik M, Zeman K, and Kilpatrick DC.

Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system. *Clin. Exp. Immunol*, 2004; 136: 304-311.

Chapman JF, Elliott C, Knowles SM, Milkins CE, Poole GD.

(British Committee for Standards in Haematology Blood Transfusion Task Force Writing Group) **Duguid J, Boulton F, McClelland B, Smith N, Cohen H, Rowley M and Taylor J. (Transfusion Task Force Members).**

Guidelines for compatibility procedures in blood transfusion laboratories. *Trans. Med.* 2004; 14: 59-73.

Copland M, Fraser AR, Harrison SJ and Holyoake TL.

Targeting the silent minority: Emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. *Cancer Immunology Immunotherapy*, 2005; 54: 297-306.

Davidson F, Lycett C, Sablon E, Petrik J and Dow BC. Hepatitis B virus genotypes and precore mutations in Scottish blood donors. *Vox Sanguinis*, 2005; 88: 87-92.

Drummond MW, Lennard A, Brummendorf TH and Holyoake TL.

Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during the progression of CML. *Leukemia and Lymphoma*, 2004; 45:1775-1781.

Drummond MW, Hoare SF, Monaghan A, Graham SM, Alcorn MJ, Keith WN and Holyoake TL. Dysregulated expression of the major telomerase components in leukaemic stem cells. *Leukemia*, 2005; 19: 381-389.

Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, Auewarakul C, Barnett MJ, Eaves CJ and Eaves AC.

Different subsets of primary chronic myeloid leukaemia stem cells engraft immunodeficient mice and produce a model of the human disease. *Leukemia*, 2005; 19: 435-441.

Elrick LJ, Jorgensen HG, Mountford JC and Holyoake TL.

Punish the Parent not the Progeny. *Blood*, 2005; 105:1862-1866.

Foster PR. Removal of TSE agents from blood products. *Vox Sanguinis*, 2004; 87(Suppl 2): S7-S10.

Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, Clark P, Walker ID, Sattar N and Greer IA. Short and long term changes in plasma inflammatory markers associated with pre-eclampsia. *Hypertension*, 2004; 44: 708-714.

Gallagher RC. Genes. Vox Sanguinis, 2004; 87 (Suppl 1): 1-5.

Garrioch M, Sandbach J, Pirie E, Morrison A, Todd A and Green R. Reducing red cell transfusion by audit, education and a new guideline in a large teaching hospital. Transfusion Medicine, 2004; 14: 25-31.

Gibson BES, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, Durbin G. (British Committee for Standards in Haematology Blood Transfusion Task Force Writing Group) Duguid J, Boulton F, Cohen H, Smith N, McClelland DBL, Rowley M and Turner G. (Transfusion Task Force Members). Transfusion guidelines for neonates and older children. B J Haematology, 2004; 124: 433-453.

Gray A, Howell C and Pirie E. (2005) Improving blood transfusion: a patient-centred approach. Nursing Standard, 2005; 19: 38-42.

Hall AM, Cairns LS, Altmann DM, Barker RN and Urbaniak SJ. Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood, 2005; 105(5): 2175-2179.

Harrison SJ, Johnson PRE and Holyoake TL. The Scotland Leukaemia Registry and audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scottish Medical Journal, 2004; 49: 87-90.

Hornsey VS, Young DA, Docherty A, Hughes W and Prowse CV. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Trans Med. 2004; 14(5): 369-374.

Ide M, Jagdev D, Coward PY, Crook M, Barclay GR and Wilson RF. The short-term effects of treatment of chronic periodontitis on circulating levels of endotoxin, C-reactive protein, tumor necrosis factor-alpha, and interleukin-6. Journal of Periodontology, 2004; 75: 420-428.

Jordanides NE, Allan EK, McLintock LA, Copland M, Devaney M, Stewart K, Parker AN, Johnson PR, Holyoake TL and Jones BL. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant, 2005; 34: 389-395.

Kilpatrick DC, Delahooke TES, Koch C, Turner ML and Hayes PC. (2003) Mannan-binding lectin and hepatitis C infection. Clin Exp Immunol, 2003; 132: 92-95.

Kilpatrick DC, Downing I, Palmer J and Turner ML. Comparison of adult and fetal cytokine secretion during mixed lymphocyte reactions. Immunology Letters, 2004; 91: 55-61.

Kilpatrick DC, Stewart K, Allan EK, McLintock LA, Holyoake TL and Turner ML. Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency. Bone Marrow Transplant, 2005; 35: 179-181.

Kilpatrick D. The ante-antibody. The Biologist, 2004, 51(4): 194-198.

MacGregor IR. Screening assays for transmissible spongiform encephalopathies (TSEs). Vox Sanguinis, 2004; 87 (Suppl 2); 3-6.

MacGregor IR and Prowse CV. Impacts and concerns for vCJD in blood transfusion: current status. Curr. Mol. Med. 2004; 4(4): 361-373.

Mackie A, Wang W, Hause B, Peumans WJ, Smagge G, Van Damme EJM and Fraser RH. The lectin from Glechoma hederacea is Tn-antigen specific. Vox Sanguinis, 2004: 87, (Suppl 3); 39.

Newsome PN, Johannessen I, Boyle S, Dalakas E, McAulay KA, Samuel K, Rae R, Forrester L, Turner ML, Hayes PC, Harrison DJ, Bickmore WA and Plevris JN. Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology, 2003; 124: 1891-1900.

Osborne WL, Holyoake TL, McQuaker IG and Parker AN. Fatal peripheral neuropathy following FLA chemotherapy. Clin. Lab. Haematology, 2004; 26: 295-296.

Prowse CV. International Forum on Extended Platelet Storage. Vox Sanguinis, 2004; 86: 203-223.

Prowse CV. vCJD in Transfusion. In: Proceedings of a Consensus Conference: The Screening of Blood Donors for Variant CJD. Eds. Blajchman MA, Goldman M, Webert KE, Vamvakas EC, Hannon J and Delage G. Transfusion Medicine Reviews, 2004; 18: 73-92.

Publications/Journals

Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Brenkel I, Walker I, Greaves M, Regan L and Greer IA.

Thrombophilia in pregnancy: a systematic review. *Br. J. Haematology*, 2004; 125: S1.

Stainsby D, Cohen H, Jones H, Knowles S, Milkins C, Chapman C, Gibson B, Davison K, Norfolk DR, Taylor C, Revill J, Asher D, Atterbury CLJ and Gray A.

(Writing Group on behalf of the SHOT Steering Group – McClelland DBL et al). Serious Hazards of Transfusion. Summary of annual report 2003. *Biomedical Scientist*, 2004; (August): 840-843 & Manchester SHOT office 88 pp.

Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DBL and Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. *Br. J. Haematology*, 2004; 126: 139-152.

Van den Broeke T, Dumont LJ, Hunter S, Nixon J, Murphy S, Roger J, Herschel L, AuBuchon JP, Gulliksson H, Dengler T, Hornsey V and Prowse C.

Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Platelet storage solution affects on the accuracy of laboratory tests for platelet function: a multi-laboratory study. *Vox Sanguinis*, 2004; 86(3): 183-188.

Walsh TS, Garrioch M, Maciver C, Lee RJ, MacKirdy F, McClelland DB, Kinsella J and Wallis C. ATICS Study Group. Red cell requirements for intensive care units adhering to evidence-based transfusion guidelines. *Vox Sanguinis*, 2004; 87 (Suppl 3): 7 and *Transfusion*, 2004; 44: 1405-1411.

Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Amlot PL, Crawford DH and Haque T. Establishment and characterisation of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. *J. Immunotherapy*, 2004; 27 (4): 309-316.

Win N, Rowley M, Pollard C, Beard J, Hambley H and Booker M. Severe gestational (incidental) thrombocytopenia: To treat or not to treat. *Hematology*, 2005; 10(1): 69-72.

Publications in Books

Holyoake T. Oncogenomics: molecular approaches to cancer. Ed. C Brenner and D Duggan. *Oncogenomics (Book brief)*, June 2004.

Holyoake T and Copland M. Imatinib Mesylate. Ed. David Webb, David Flockhart and Ken Paterson. *Year in Therapeutics*, 2005.

McClelland B. Who needs transfusion? In: *A Manual for Blood Conservation*. Eds. Thomas D, Thompson J, Ridler B. Shrewsbury, Harley tfm Publishing, ch. 4, 35-44, 2005.

Turner ML. Variant CJD. In: *Practical Transfusion Medicine*, 2nd Edition. Murphy MF, Pamphilon DH (eds). Oxford: Blackwell Science, 2004.

Walsh TS, Saleh E and McLellan SA. Epidemiology, etiology, and tolerance of anemia during critical illness. In: *Yearbook of Intensive Care and Emergency Medicine*, Ed. Vincent, J-L. Berlin, Springer-Verlag, 731-741, 2004.

Correspondence

Allan EK, Jordanides NE, McIntock LA, Copland M, Devaney M, Stewart K, Parker AN, Johnson PRE, Holyoake TL and Jones BL. Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. *Br J Haematology*, 2005; 128: 578-579.

Church NI, Dallal HJ, Palmer KR, Masson J, Mowat A, Johnston DA, Radin E, Turner M, Fullarton G and Prescott RJ. Discussion on a randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer. *Gastroenterology*, 2004; 126: 940.

Deininger MW, Holyoake TL. Can we afford to let sleeping dogs lie? *Blood*, 2005; 105: 1840-1841.

Down JF, Barclay GR, Bennett-Guerrero E, Hamilton-Davies C, Stephens R, Grocott MPW and Mythen MG. A descriptive study of the variation in baseline levels of anti-endotoxin core antibodies between US and UK populations. *Journal of Endotoxin Research*, 2004; 10: 195-196.

Gray A and Illingworth J. Right blood, right patient, right time. RCN guidance for improving transfusion practice, 2004; London, Royal College of Nursing, 11.

Jorgensen H, Copland M and Holyoake T. Response to Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukaemia. *Quintas-Cardama et al. Cancer*, 2005; Jan 1;103(1): 210-211.

Klein NJ and Kilpatrick DC. Is there a role for mannan/mannose-binding lectin (MBL) in defence against infection following chemotherapy for cancer? *Clin. Exp. Immunol.* 2004; 138: 202-204.

McClelland B and Contreras M. Appropriateness and safety of blood transfusion. *BMJ*, 2005; 330: 104-105.

McClelland DBL and Contreras M. Effectiveness and safety of blood transfusion: have we lost the plot? *Journal of the Royal College of Physicians of Edinburgh*, 2005; 35: 2-4.

McIntock LA, Jordanides NE, Allan EK, Copland M, Stewart K, Parker A, Devaney M, Holyoake TL and Jones BL. The use of a risk group stratification in the management of invasive fungal infection: A prospective validation. *Br. J. Haematology*, 2004; 124: 403-404.

McIntock LA, Holyoake TL and Jones BL. Published rather than proposed EORTC/MSG definitions for IFI must be applied to allow standardisation in clinical trials. *Clinical Infectious Diseases*, 2004; June 1; 38(11): 1648-1649.

Nussey F and Turner ML. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells by Pinedo et al. *European Journal of Cancer*, 2003; 39: 1039-1040.

Rawlinson PSM, Brown G, Paterson G and Clark P. The integration of data logging and transport technology to provide waste-free emergency transfusion support to distant hospital facilities. *Trans. Med.* 2004; 14: 323-324.

Turner ML. Spongiform Encephalopathy and variant Creutzfeldt Jakob Disease. *Blood Therapies in Medicine*, 2004; 4(2): 38-39.

Walsh TS and McClelland DBL. When should we transfuse critically ill and perioperative patients with known coronary artery disease? *Br. J. Anaesthesia*, 2003; 90: 719-722.

Walsh TS and McClelland B. Does the age of blood matter? The authors reply: *Critical Care Medicine*, 2004; 32: 1443.

Walsh TS and McClelland B. (2004) Does the storage time of transfused red blood cells influence critically ill patients? The authors reply: *Critical Care Medicine*, 2004; 32: 1444-1445.

Active Patents

Patent Holders	Patent Title	Patent Number
MacGregor IR, Hardy JC and Drummond O	Thrombin Preparation	EP – 813 598 B1 – 2004
Foster PR	Treating protein-containing liquids	EP – 1 144 015 B1 – 2004

Active Grants

Grant Awarders/ Holders	Subject	Overall sum (£) + years & end date
Department of Health		
Clinton M, Anstee D and MacGregor IR	Screening blood for high risk donations (with Roslin Institute and National Blood Service)	517,967 (3 years to October 2005)
Sharma H, Ellis B, Prescott M, Dealler S, Nestorov I and Turner M	Comparative pharmacokinetics of pentosan polysulphate in mice and humans	238,007 (3 years to August 2004)
Head M, MacGregor IR, Farquhar C and Connolly J	Novel application-specific monoclonal antibodies to prion protein (with Institute of Animal Health, CJDSU and Strathclyde University)	411,182 (3 years to January 2006)
Houston F, Prowse C, Turner M, MacGregor I, Hornsey V, Hunter N, Foster J and Groschup M	The effect of leucodepletion on transmission of BSE by transfusion of sheep blood components	3,424,382 (6 years to January 2011)
Glasgow Royal Infirmary Endowments		
Holyoake TL and Jorgensen H	G-CSF and imatinib mesylate intermittently	9,000 (6 years to January 2011)
Holyoake TL	In support of Glasgow University PhD Studentship on Stem Cells	50,000 (over 3 years to 2005)
Holyoake TL et al	Consumables grant for Glivec Studies	9,000 (3 years to June 2005)
Holyoake TL	Consumables grant for Stem Cell Profiling	9,500 (3 years to June 2005)
Holyoake TL et al	Consumables grant	4,600 (2 years to 2005)
Schering-Plough Research Institute		
Holyoake TL et al	In support of University of Strathclyde PhD studentship on Cell Therapy	35,000 (over 3 years to 2005)

Active Grants

Grant Awarders/ Holders	Subject	Overall sum (£) + years & end date
Sylvia Aitken Charity Trust Holyoake T and Franklin I	Development and characterisation of multiple myeloma tumour-specific immunological responses using tumour peptide heat-shock protein (HSP) complexes for stimulation	115,000 (3 years to June 2005))
Kay Kendall Leukaemia Fund Holyoake et al	Research Fellowship & consumables grant	139,000 (over 3 years to May 2005)
Leukaemia Research Trust Scotland Holyoake TL and Copland M	In vitro investigations of novel drug combinations in CML	12,500 (18 months to September 2006)
Leukaemia Research Fund Holyoake, TL et al	Microarray analysis of CML stem cells	16,000 18 months to March 2006)
Holyoake TL	Pilot study of continuous imatinib mesylate vs. pulsed IM with/without G-CSF in CML patients who have achieved a CCR	35,540 (2 years to December 2006)
Holyoake TL et al	FACS in studies of normal and malignant human and murine haemopoiesis	142,233 (3 years to December 2007)
Holyoake TL, Clark R and Mountford J	An investigation of the role of ABC transporters in mediating resistance of quiescent CML stem cells to imatinib	279,789 (3 years to September 2007)
Holyoake TL et al	Research Fellow & Research Technician grant	264,723 (3 years to August 2006)
Holyoake et al	Research Assistant with consumables grant	150,541 (3 years to July 2007)
Medical Research Council Holyoake TL et al	Clinical Research Fellowship & consumables grant	154,000 (3 years to September 2006)
Chief Scientist Office – Scottish Executive Health Department (CSO SEHD) Holyoake TL and Mountford J	Purchase of Agilent Bioanalyser	15,000 (In year 2004)
Holyoake TL and Mountford J	Purchase of Taqman PCR Real time	34,160 (In year 2004)
Holyoake TL et al	Research Assistant & consumables grant	174,000 (3 years to August 2006)
Holyoake TL and Parker A	Factors affecting recruitment to haemato-oncology clinical trials in North Glasgow	45,000 (2 years to January 2007)

Active Grants

Grant Awarders/ Holders	Subject	Overall sum (£) + years & end date
Chief Scientist Office – Scottish Executive Health Department (CSO SEHD)		
Moss M, Urbaniak SJ and Fraser RH	Synthetic peptides as potential blood grouping diagnostic reagents	152,078 (over 3 years to May 2006)
Newsome P, Harrison D, Turner ML, Forrester L, Pleveris J, Samuel K and Bickmore W	In vivo study of hepatocytic differentiation of human haematopoietic stem cells and their reparative role in liver injury	183,926 (over 3 years)
Rameesh K, Turner ML and Dhillon B	Corneal epithelial stem cell grafting	20,000 (over 9 months)
Porteous DJ, Turner M, Kerr S, Newby Dand Wild S	Collection of a control cohort from the Scottish population as a national DNA resource for human genetics studies	181,806 (2 years to November 2006)
Richard Rockefeller Foundation		
Holyoake TL	Dr Richard Rockefeller Donation	\$30,000 US (In year 2005)
NHS Lothian University Hospitals Division		
Mills NL, Tura O, Barclary, GR and Newby DE	The effects of percutaneous coronary intervention on endothelial progenitor cell mobilisation	6,000 (6 months to August 2005)
Davies JM, Roddie PH, Turner ML and Barclay GR	Characterisation and ex vivo expansion of adult peripheral blood and bone marrow haematopoietic and other stem cells	75,000 (4 years to January 2006)
Scottish Enterprise: Proof of Concept Funding		
Ghazal P and Petrik J	Protein microarrays for blood screening	198,928 (2 years to April 2005)
Scottish Enterprise: Royal Society of Edinburgh		
Cairns L, Barker R and Urbaniak SJ	Peptide immunotherapy to prevent diseases caused by blood group reactions	33,638 (over 2 years to 2005)
DiaMed AG (Commercial funding)		
Fraser RH et al	Development of novel diagnostic monoclonal antibodies	Rolling grant (each year from June 1994) 50,000 SwFr (25,000)
European Commission Framework 6		
Lowe K, Prowse CV et al	Eurobloodsubstitutes Proposal No 503023	54,000 (2 years to May 2006)
Urbaniak SJ et al	Special non-invasive Advances in Foetal & Neonatal Evaluation Work (SAFE) on non-invasive foetal RhD genotyping and evaluation	Share of 12m euro over 5 years from 2003 with 19 core laboratories